Your browser doesn't support javascript.
loading
Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneity.
Hoefflin, Rouven; Lahrmann, Bernd; Warsow, Gregor; Hübschmann, Daniel; Spath, Cathleen; Walter, Britta; Chen, Xin; Hofer, Luisa; Macher-Goeppinger, Stephan; Tolstov, Yanis; Korzeniewski, Nina; Duensing, Anette; Grüllich, Carsten; Jäger, Dirk; Perner, Sven; Schönberg, Gita; Nyarangi-Dix, Joanne; Isaac, Sanjay; Hatiboglu, Gencay; Teber, Dogu; Hadaschik, Boris; Pahernik, Sascha; Roth, Wilfried; Eils, Roland; Schlesner, Matthias; Sültmann, Holger; Hohenfellner, Markus; Grabe, Niels; Duensing, Stefan.
Afiliação
  • Hoefflin R; Section of Molecular Urooncology, Department of Urology, University of Heidelberg School of Medicine, Medical Faculty Heidelberg, Im Neuenheimer Feld 517, D-69120 Heidelberg, Germany.
  • Lahrmann B; Hamamatsu Tissue Imaging and Analysis (TIGA) Center, BioQuant, University of Heidelberg, Im Neuenheimer Feld 267, D-60120 Heidelberg, Germany.
  • Warsow G; Division of Theoretical Bioinformatics (B080), German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany.
  • Hübschmann D; Division of Theoretical Bioinformatics (B080), German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany.
  • Spath C; Department for Bioinformatics and Functional Genomics, Institute for Pharmacy and Molecular Biotechnology (IPMB) and BioQuant, University of Heidelberg, Im Neuenheimer Feld 267, D-69120 Heidelberg, Germany.
  • Walter B; Department of Pediatric Immunology, Hematology and Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 430, D-69120 Heidelberg, Germany.
  • Chen X; National Center for Tumor Diseases, Department of Medical Oncology, Im Neuenheimer Feld 460, D-69120 Heidelberg, Germany.
  • Hofer L; Department of Pathology, University of Heidelberg School of Medicine, Im Neuenheimer Feld 224, D-69120 Heidelberg, Germany.
  • Macher-Goeppinger S; Section of Molecular Urooncology, Department of Urology, University of Heidelberg School of Medicine, Medical Faculty Heidelberg, Im Neuenheimer Feld 517, D-69120 Heidelberg, Germany.
  • Tolstov Y; Department of Urology, University of Heidelberg School of Medicine, Im Neuenheimer Feld 110, D-69120 Heidelberg, Germany.
  • Korzeniewski N; Center for Kidney Tumors, National Center for Tumor Diseases and University of Heidelberg School of Medicine, Im Neuenheimer Feld 460, D-69120 Heidelberg, Germany.
  • Duensing A; Department of Pathology, University of Heidelberg School of Medicine, Im Neuenheimer Feld 224, D-69120 Heidelberg, Germany.
  • Grüllich C; Section of Molecular Urooncology, Department of Urology, University of Heidelberg School of Medicine, Medical Faculty Heidelberg, Im Neuenheimer Feld 517, D-69120 Heidelberg, Germany.
  • Jäger D; Section of Molecular Urooncology, Department of Urology, University of Heidelberg School of Medicine, Medical Faculty Heidelberg, Im Neuenheimer Feld 517, D-69120 Heidelberg, Germany.
  • Perner S; University of Pittsburgh Cancer Institute, Cancer Therapeutics Program, 5117 Centre Avenue, Pittsburgh, Pennsylvania 15232, USA.
  • Schönberg G; National Center for Tumor Diseases, Department of Medical Oncology, Im Neuenheimer Feld 460, D-69120 Heidelberg, Germany.
  • Nyarangi-Dix J; Center for Kidney Tumors, National Center for Tumor Diseases and University of Heidelberg School of Medicine, Im Neuenheimer Feld 460, D-69120 Heidelberg, Germany.
  • Isaac S; National Center for Tumor Diseases, Department of Medical Oncology, Im Neuenheimer Feld 460, D-69120 Heidelberg, Germany.
  • Hatiboglu G; Center for Kidney Tumors, National Center for Tumor Diseases and University of Heidelberg School of Medicine, Im Neuenheimer Feld 460, D-69120 Heidelberg, Germany.
  • Teber D; Institute of Pathology, University Hospital Lübeck and Leibniz Research Center Borstel, Ratzeburger Allee 160, D-23538 Lübeck, Germany.
  • Hadaschik B; Department of Urology, University of Heidelberg School of Medicine, Im Neuenheimer Feld 110, D-69120 Heidelberg, Germany.
  • Pahernik S; Center for Kidney Tumors, National Center for Tumor Diseases and University of Heidelberg School of Medicine, Im Neuenheimer Feld 460, D-69120 Heidelberg, Germany.
  • Roth W; Department of Urology, University of Heidelberg School of Medicine, Im Neuenheimer Feld 110, D-69120 Heidelberg, Germany.
  • Eils R; Center for Kidney Tumors, National Center for Tumor Diseases and University of Heidelberg School of Medicine, Im Neuenheimer Feld 460, D-69120 Heidelberg, Germany.
  • Schlesner M; National Center for Tumor Diseases, Department of Medical Oncology, Im Neuenheimer Feld 460, D-69120 Heidelberg, Germany.
  • Sültmann H; Center for Kidney Tumors, National Center for Tumor Diseases and University of Heidelberg School of Medicine, Im Neuenheimer Feld 460, D-69120 Heidelberg, Germany.
  • Hohenfellner M; Department of Urology, University of Heidelberg School of Medicine, Im Neuenheimer Feld 110, D-69120 Heidelberg, Germany.
  • Grabe N; Center for Kidney Tumors, National Center for Tumor Diseases and University of Heidelberg School of Medicine, Im Neuenheimer Feld 460, D-69120 Heidelberg, Germany.
  • Duensing S; Department of Urology, University of Heidelberg School of Medicine, Im Neuenheimer Feld 110, D-69120 Heidelberg, Germany.
Nat Commun ; 7: ncomms11845, 2016 06 13.
Article em En | MEDLINE | ID: mdl-27291893
ABSTRACT
Intratumoural heterogeneity (ITH) is a major cause of cancer-associated lethality. Extensive genomic ITH has previously been reported in clear cell renal cell carcinoma (ccRCC). Here we address the question whether ITH increases with malignant progression and can hence be exploited as a prognostic marker. Unexpectedly, precision quantitative image analysis reveals that the degree of functional ITH is virtually identical between primary ccRCCs of the lowest stage and advanced, metastatic tumours. Functional ITH was found to show a stage-independent topological pattern with peak proliferative and signalling activities almost exclusively in the tumour periphery. Exome sequencing of matching peripheral and central primary tumour specimens reveals various region-specific mutations. However, these mutations cannot directly explain the zonal pattern suggesting a role of microenvironmental factors in shaping functional ITH. In conclusion, our results indicate that ITH is an early and general characteristic of malignant growth rather than a consequence of malignant progression.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Heterogeneidade Genética / Microambiente Tumoral / Neoplasias Renais Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Heterogeneidade Genética / Microambiente Tumoral / Neoplasias Renais Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Alemanha